Modified model incorporating sarcopenia and myosteatosis for predicting severe hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: Multicenter study

Figure 6 Comparison of the cumulative incidence rates of post-transjugular intrahepatic portosystemic shunt severe hepatic encephalopathy between the higher-risk and lower-risk groups stratified by the modified predictive model. A: Training cohort; B: Internal validation cohort; C: External validation cohort. The incidence rates of severe hepatic encephalopathy in the training cohort were 41/118 (34.7%) for the higher-risk group and 16/177 (9.0%) for the lower-risk group. In the internal validation cohort, the incidence rates were 13/37 (35.1%) for the higher-risk group and 8/87 (9.2%) for the lower-risk group. In the external validation cohort, the incidence rates were 19/45 (42.2%) for the higher-risk group and 11/126 (8.7%) for the lower-risk group.